Demographic and clinical characteristics of the study population summarised by type of treatment
| Zofenopril (n=1808) | Placebo (n=951) | Lisinopril (n=520) | Ramipril (n=351) | p Value | |
|---|---|---|---|---|---|
| Age (years, mean±SD) | 61±11 | 63±11 | 59±10 | 61±11 | <0.001 |
| Males (n, %) | 1357 (75) | 705 (74) | 395 (76) | 276 (79) | 0.396 |
| BMI (kg/m2, mean±SD) | 27±4 | 26±4 | 27±4 | 28±4 | <0.001 |
| Major CV risk factors (n, %) | 315 (17) | 182 (19) | 83 (16) | 88 (25) | <0.001 |
| Diabetes (n, %) | 1203 (67) | 640 (67) | 283 (54) | 288 (82) | <0.001 |
| Hypertension (n, %) | 786 (45) | 486 (52) | 259 (51) | 131 (40) | <0.001 |
| Hypercholesterolaemia (n, %) | 1435 (79) | 760 (80) | 386 (74) | 279 (80) | 0.054 |
Data are shown as absolute (n) and relative (%) frequencies for categorical variables and as mean (±SD) for continuous variables. p Values refer to the statistical significance of the difference across the four treatment groups (χ2 test for categorical variables and ANOVA for continuous variables).
ANOVA, analysis of variance; BMI, body mass index; CV, cardiovascular.